221 related articles for article (PubMed ID: 30292334)
1. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Nguyen E; Coleman CI; Kohn CG; Weeda ER
Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine for the treatment of refractory angina in a veterans population.
Greene RS; Rangel RM; Edwards KL; Chastain LM; Brouse SD; Alvarez CA; Collins LJ; Brilakis ES; Banerjee S
Cardiovasc Revasc Med; 2012; 13(2):141.e1-5. PubMed ID: 21856249
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Angina: Where Are We?
Balla C; Pavasini R; Ferrari R
Cardiology; 2018; 140(1):52-67. PubMed ID: 29874661
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
8. Antianginal Agents for the Management of Stable Ischemic Heart Disease: A Review.
Mody P; Sidhu MS; Brilakis ES; Sacco JD; Banerjee S; Boden WE
Cardiol Rev; 2016; 24(4):177-89. PubMed ID: 26274534
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
10. Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy.
Meyer N; Tran O; Hartsfield C; Nguyen L; Kazi DS; Koch B
Am J Cardiol; 2019 May; 123(10):1602-1609. PubMed ID: 30832963
[TBL] [Abstract][Full Text] [Related]
11. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
[TBL] [Abstract][Full Text] [Related]
12. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
13. Antianginal medications and long-term outcomes after elective catheterization in patients with coronary artery disease.
Shen L; Vavalle JP; Broderick S; Shaw LK; Douglas PS
Clin Cardiol; 2016 Dec; 39(12):721-727. PubMed ID: 28026916
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.
Kones R
Vasc Health Risk Manag; 2010 Sep; 6():749-74. PubMed ID: 20859545
[TBL] [Abstract][Full Text] [Related]
15. Old and New Drugs for Treatment of Stable Angina.
Rognoni A
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):3. PubMed ID: 26245657
[No Abstract] [Full Text] [Related]
16. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM
Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896
[TBL] [Abstract][Full Text] [Related]
17. CLINICAL PRACTICE. Chronic Stable Angina.
Ohman EM
N Engl J Med; 2016 Mar; 374(12):1167-76. PubMed ID: 27007960
[No Abstract] [Full Text] [Related]
18. Trials and tribulations associated with angina and traditional therapeutic approaches.
Deedwania PC; Carbajal EV; Bobba VR
Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I16-24. PubMed ID: 18373326
[TBL] [Abstract][Full Text] [Related]
19. Use of ranolazine in patients with stable angina pectoris.
Khera S; Kolte D; Aronow WS
Cardiology; 2014; 128(3):251-8. PubMed ID: 24852049
[TBL] [Abstract][Full Text] [Related]
20. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
Motivala AA; Parikh V; Roe M; Dai D; Abbott JD; Prasad A; Mukherjee D
JACC Cardiovasc Interv; 2016 Aug; 9(16):1639-48. PubMed ID: 27539683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
